Natural Thiopeptides As a Privileged Scaffold for Drug Discovery and Therapeutic Development
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Micromonospora: an Important Microbe for Biomedicine and Potentially for Biocontrol and Biofuels
ARTICLE IN PRESS Soil Biology & Biochemistry xxx (2009) 1e7 Contents lists available at ScienceDirect Soil Biology & Biochemistry journal homepage: www.elsevier.com/locate/soilbio Review Micromonospora: An important microbe for biomedicine and potentially for biocontrol and biofuels Ann M. Hirsch a,b,*, Maria Valdés c a Department of Molecular, Cell and Developmental Biology, University of California, 405 Hilgard Avenue, Los Angeles, CA 90095-1606, USA b Molecular Biology Institute, University of California, 405 Hilgard Avenue, Los Angeles, CA 90095-1606, USA c Departamento de Microbiología, Escuela Nacional de Ciencias Biológicas, I. P. N., Plan de Ayala y Carpio, 11340, Mexico article info abstract Article history: Micromonospora species have long been recognized as important sources of antibiotics and also for their Received 2 September 2009 unusual spores. However, their involvement in plant-microbe associations is poorly understood although Received in revised form several studies demonstrate that Micromonospora species function in biocontrol, plant growth promo- 17 November 2009 tion, root ecology, and in the breakdown of plant cell wall material. Our knowledge of this generally Accepted 20 November 2009 understudied group of actinomycetes has been greatly advanced by the increasing number of reports of Available online xxx their associations with plants, by the deployment of DNA cloning and molecular systematics techniques, and by the recent application of whole genome sequencing. Efforts to annotate the genomes of several Keywords: Actinomycetes Micromonospora species are underway. This information will greatly augment our knowledge of these Biocontrol versatile microorganisms. Hydrolytic enzymes Ó 2009 Elsevier Ltd. All rights reserved. Secondary metabolites 1. Introduction species also produce anti-tumor antibiotics (lomaiviticins A and B, tetrocarcin A, LL-E33288 complex, etc.) and anthracycline antibi- Although the genus Micromonospora has long been recognized otics. -
Cyanobacterial Peptide Toxins
CYANOBACTERIAL PEPTIDE TOXINS CYANOBACTERIAL PEPTIDE TOXINS 1. Exposure data 1.1 Introduction Cyanobacteria, also known as blue-green algae, are widely distributed in fresh, brackish and marine environments, in soil and on moist surfaces. They are an ancient group of prokaryotic organisms that are found all over the world in environments as diverse as Antarctic soils and volcanic hot springs, often where no other vegetation can exist (Knoll, 2008). Cyanobacteria are considered to be the organisms responsible for the early accumulation of oxygen in the earth’s atmosphere (Knoll, 2008). The name ‘blue- green’ algae derives from the fact that these organisms contain a specific pigment, phycocyanin, which gives many species a slightly blue-green appearance. Cyanobacterial metabolites can be lethally toxic to wildlife, domestic livestock and even humans. Cyanotoxins fall into three broad groups of chemical structure: cyclic peptides, alkaloids and lipopolysaccharides. Table 1.1 gives an overview of the specific toxic substances within these broad groups that are produced by different genera of cyanobacteria together, with their primary target organs in mammals. However, not all cyanobacterial blooms are toxic and neither are all strains within one species. Toxic and non-toxic strains show no predictable difference in appearance and, therefore, physicochemical, biochemical and biological methods are essential for the detection of cyanobacterial toxins. The most frequently reported cyanobacterial toxins are cyclic heptapeptide toxins known as microcystins which can be isolated from several species of the freshwater genera Microcystis , Planktothrix ( Oscillatoria ), Anabaena and Nostoc . More than 70 structural variants of microcystins are known. A structurally very similar class of cyanobacterial toxins is nodularins ( < 10 structural variants), which are cyclic pentapeptide hepatotoxins that are found in the brackish-water cyanobacterium Nodularia . -
Genomic and Phylogenomic Insights Into the Family Streptomycetaceae Lead
1 Supplementary Material 2 Genomic and phylogenomic insights into the family Streptomycetaceae lead 3 to proposal of Charcoactinosporaceae fam. nov. and 8 novel genera with 4 emended descriptions of Streptomyces calvus 5 Munusamy Madhaiyan1, †, *, Venkatakrishnan Sivaraj Saravanan2, †, Wah-Seng See-Too3, † 6 1Temasek Life Sciences Laboratory, 1 Research Link, National University of Singapore, 7 Singapore 117604; 2Department of Microbiology, Indira Gandhi College of Arts and Science, 8 Kathirkamam 605009, Pondicherry, India; 3Division of Genetics and Molecular Biology, 9 Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, 10 Malaysia 1 11 Table S3. List of the core genes in the genome used for phylogenomic analysis. NCBI Protein Accession Gene WP_074993204.1 NUDIX hydrolase WP_070028582.1 YggS family pyridoxal phosphate-dependent enzyme WP_074992763.1 ParB/RepB/Spo0J family partition protein WP_070022023.1 lipoyl(octanoyl) transferase LipB WP_070025151.1 FABP family protein WP_070027039.1 heat-inducible transcriptional repressor HrcA WP_074992865.1 folate-binding protein YgfZ WP_074992658.1 recombination protein RecR WP_074991826.1 HIT domain-containing protein WP_070024163.1 adenylosuccinate synthase WP_009190566.1 anti-sigma regulatory factor WP_071828679.1 preprotein translocase subunit SecG WP_070026304.1 50S ribosomal protein L13 WP_009190144.1 30S ribosomal protein S5 WP_014674378.1 30S ribosomal protein S8 WP_070026314.1 50S ribosomal protein L5 WP_009300593.1 30S ribosomal protein S13 WP_003998809.1 -
(12) United States Patent (10) Patent No.: US 9,642,912 B2 Kisak Et Al
USOO9642912B2 (12) United States Patent (10) Patent No.: US 9,642,912 B2 Kisak et al. (45) Date of Patent: *May 9, 2017 (54) TOPICAL FORMULATIONS FOR TREATING (58) Field of Classification Search SKIN CONDITIONS CPC ...................................................... A61K 31f S7 (71) Applicant: Crescita Therapeutics Inc., USPC .......................................................... 514/171 Mississauga (CA) See application file for complete search history. (72) Inventors: Edward T. Kisak, San Diego, CA (56) References Cited (US); John M. Newsam, La Jolla, CA (US); Dominic King-Smith, San Diego, U.S. PATENT DOCUMENTS CA (US); Pankaj Karande, Troy, NY (US); Samir Mitragotri, Santa Barbara, 5,602,183 A 2f1997 Martin et al. CA (US); Wade A. Hull, Kaysville, UT 5,648,380 A 7, 1997 Martin 5,874.479 A 2, 1999 Martin (US); Ngoc Truc-ChiVo, Longueuil 6,328,979 B1 12/2001 Yamashita et al. (CA) 7,001,592 B1 2/2006 Traynor et al. 7,795,309 B2 9/2010 Kisak et al. (73) Assignee: Crescita Therapeutics Inc., 8,343,962 B2 1/2013 Kisak et al. Mississauga (CA) 8,513,304 B2 8, 2013 Kisak et al. 8,535,692 B2 9/2013 Pongpeerapat et al. (*) Notice: Subject to any disclaimer, the term of this 9,308,181 B2* 4/2016 Kisak ..................... A61K 47/12 patent is extended or adjusted under 35 2002fOOO6435 A1 1/2002 Samuels et al. 2002fOO64524 A1 5, 2002 Cevc U.S.C. 154(b) by 204 days. 2005, OO 14823 A1 1/2005 Soderlund et al. This patent is Subject to a terminal dis 2005.00754O7 A1 4/2005 Tamarkin et al. -
First Evidence of Production of the Lantibiotic Nisin P Enriqueta Garcia-Gutierrez1,2, Paula M
www.nature.com/scientificreports OPEN First evidence of production of the lantibiotic nisin P Enriqueta Garcia-Gutierrez1,2, Paula M. O’Connor2,3, Gerhard Saalbach4, Calum J. Walsh2,3, James W. Hegarty2,3, Caitriona M. Guinane2,5, Melinda J. Mayer1, Arjan Narbad1* & Paul D. Cotter2,3 Nisin P is a natural nisin variant, the genetic determinants for which were previously identifed in the genomes of two Streptococcus species, albeit with no confrmed evidence of production. Here we describe Streptococcus agalactiae DPC7040, a human faecal isolate, which exhibits antimicrobial activity against a panel of gut and food isolates by virtue of producing nisin P. Nisin P was purifed, and its predicted structure was confrmed by nanoLC-MS/MS, with both the fully modifed peptide and a variant without rings B and E being identifed. Additionally, we compared its spectrum of inhibition and minimum inhibitory concentration (MIC) with that of nisin A and its antimicrobial efect in a faecal fermentation in comparison with nisin A and H. We found that its antimicrobial activity was less potent than nisin A and H, and we propose a link between this reduced activity and the peptide structure. Nisin is a small peptide with antimicrobial activity against a wide range of pathogenic bacteria. It was originally sourced from a Lactococcus lactis subsp. lactis isolated from a dairy product1 and is classifed as a class I bacteri- ocin, as it is ribosomally synthesised and post-translationally modifed2. Nisin has been studied extensively and has a wide range of applications in the food industry, biomedicine, veterinary and research felds3–6. -
Isolation and Identification of Actinomycetes Strains from Switzerland and Their Biotechnological Potential
382 CHIMIA 2020, 74, No. 5 BUILDING BRIDGES BETWEEN BIOTECHNOLOGY AND CHEMISTRY – IN MEMORIAM ORESTE GHISALBA doi:10.2533/chimia.2020.382 Chimia 74 (2020) 382–390 © F. Arn, D. Frasson, I. Kroslakova, F. Rezzonico, J. F. Pothier, R. Riedl, M. Sievers Isolation and Identification of Actinomycetes Strains from Switzerland and their Biotechnological Potential Fabienne Arna§, David Frassonb§, Ivana Kroslakovab, Fabio Rezzonicoc, Joël F. Pothierc, Rainer Riedla, and Martin Sieversb* Abstract: Actinomycetes strains isolated from different habitats in Switzerland were investigated for production of antibacterial and antitumoral compounds. Based on partial 16S rRNA gene sequences, the isolated strains were identified to genus level. Streptomyces as the largest genus of Actinobacteria was isolated the most frequently. A screening assay using the OmniLog instrument was established to facilitate the detection of active compounds from actinomycetes. Extracts prepared from the cultivated strains able to inhibit Staphylococcus aureus and Escherichia coli were further analysed by HPLC and MALDI-TOF MS to identify the produced antibiotics. In this study, the bioactive compound echinomycin was identified from two isolated Streptomyces strains. Natural compounds similar to TPU-0037-C, azalomycin F4a 2-ethylpentyl ester, a derivative of bafilomycin A1, milbe- mycin-α8 and dihydropicromycin were detected from different isolated Streptomyces strains. Milbemycin-α8 showed cytotoxic activity against HT-29 colon cancer cells. The rare actinomycete, Micromonospora sp. Stup16_ C148 produced a compound that matches with the antibiotic bottromycin A2. The draft genome sequence from Actinokineospora strain B136.1 was determined using Illumina and nanopore-based technologies. The isolated strain was not able to produce antibacterial compounds under standard cultivation conditions. -
Autogenous Transcriptional Activation of a Thiostrepton- Induced Gene in Streptomyces Lividans
The EMBO Journal vol.12 no.8 pp.3183-3191, 1993 Autogenous transcriptional activation of a thiostrepton- induced gene in Streptomyces lividans David J.Holmes1, Jose L.Caso2 synthesis is irreversibly blocked (Cundliffe, 1971). Although and Charles J.Thompson3 it can be demonstrated in vitro that thiostrepton binds specifically to a region of base pairing extending for 58 Institut Pasteur, 28 rue du Docteur Roux, 75015 Paris, France nucleotides in the ribosomal RNA (Ryan et al., 1991; 'Present address: SmithKlineBeecham Pharmaceuticals, Departamento Thompson and Cundliffe, 1991) but not to ribosomal de Biotecnologfa, C/Santiago Grisolia s/n, Tres Cantos (Madrid), Spain proteins, both components are thought to play a role in 2Present address: Universidad de Oviedo, Facultad de Medicina, forming a stable drug -ribosome complex. Resistance to the Departamento de Biologfa Funcional, Area de Microbiologfa, c/Julian antibiotic in S.azureus is conferred by the action of a Claverfa, s/n, 33006-Oviedo, Spain methylase which modifies a specific nucleotide within this 3Present address: Biozentrum, der Universitit Basel, Department of Microbiology, Klingelbergstrasse 70, CH-4056 Basel, Switzerland sequence (Cundliffe, 1978; Thompson et al., 1982a). The gene encoding the methylase, tsr, has been incorporated into Communicated by H.Buc most streptomycete cloning vectors including p1161 (Thompson et al., 1982b) used in this study (Hopwood et al., known as an Although the antibiotic thiostrepton is best 1985) and is widely used as the primary selectable marker. inhibitor of protein synthesis, it also, at extremely low Ribosomes isolated from S. azureus or S. lividans containing concentrations (< 10-9 M), induces the expression of a in Streptomyces the cloned tsr gene do not detectably bind thiostrepton regulon of unknown function certain (Thompson et al., 1982a). -
Identification of the Thiazolyl Peptide GE37468 Gene Cluster from Streptomyces ATCC 55365 and Heterologous Expression in Streptomyces Lividans
Identification of the thiazolyl peptide GE37468 gene cluster from Streptomyces ATCC 55365 and heterologous expression in Streptomyces lividans Travis S. Young and Christopher T. Walsh1 Harvard Medical School, Armenise D1, Room 608, 240 Longwood Avenue, Boston, MA 02115 Contributed by Christopher T. Walsh, June 29, 2011 (sent for review June 6, 2011) Thiazolyl peptides are bacterial secondary metabolites that teins (10–13). The mature antibiotic arises from a structural gene potently inhibit protein synthesis in Gram-positive bacteria and encoding a 50–60 amino acid preprotein consisting of a 40–50 malarial parasites. Recently, our laboratory and others reported amino acid N-terminal leader peptide (residues −50 to −1) and that this class of trithiazolyl pyridine-containing natural products a14–18 amino acid C-terminal region (residues +1 to +18), is derived from ribosomally synthesized preproteins that undergo which becomes the final product scaffold (3). Flanking the struc- a cascade of posttranslational modifications to produce architectu- tural gene are encoded enzymes involved in peptide maturation, rally complex macrocyclic scaffolds. Here, we report the gene which appear to mimic the biosynthetic logic for microcin B17, cluster responsible for production of the elongation factor Tu lantibiotic, and cyanobactin antibiotic peptides (14). These (EF-Tu)-targeting 29-member thiazolyl peptide GE37468 from enzymes include lantibiotic-type dehydratases that form dehydro Streptomyces ATCC 55365 and its heterologous expression in the amino acids, cyclodehydratase and dehydrogenase enzymes model host Streptomyces lividans. GE37468 harbors an unusual involved in the formation of thiazoles/oxazoles, and a novel β-methyl-δ-hydroxy-proline residue that may increase conforma- enzyme(s) involved in the formation of the central pyridine/ tional rigidity of the macrocycle and impart reduced entropic costs piperidine ring. -
Thiocillin and Micrococcin Exploit the Ferrioxamine Receptor of Pseudomonas Aeruginosa for Uptake
bioRxiv preprint doi: https://doi.org/10.1101/2020.04.23.057471; this version posted April 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 1 Thiocillin and Micrococcin Exploit the Ferrioxamine Receptor of Pseudomonas aeruginosa for Uptake 2 Derek C. K. Chan and Lori L. Burrows* 3 Michael G. DeGroote Institute for Infectious Disease Research, Department of Biochemistry and 4 Biomedical Sciences, McMaster University, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada 5 KEYWORDS: drug discovery, mechanism of uptake, thiopeptide, antimicrobial activity, siderophore, trojan 6 horse, 7 ABSTRACT 8 Thiopeptides are a class of Gram-positive antibiotics that inhibit protein synthesis. They have been 9 underutilized as therapeutics due to solubility issues, poor bioavailability, and lack of activity against 10 Gram-negative pathogens. We discovered recently that a member of this family, thiostrepton, has activity 11 against Pseudomonas aeruginosa and Acinetobacter baumannii under iron-limiting conditions. 12 Thiostrepton uses pyoverdine siderophore receptors to cross the outer membrane, and combining 13 thiostrepton with an iron chelator yielded remarkable synergy, significantly reducing the minimal 14 inhibitory concentration. These results led to the hypothesis that other thiopeptides could also inhibit 15 growth by using siderophore receptors to gain access to the cell. Here, we screened six thiopeptides for 16 synergy with the iron chelator deferasirox against P. aeruginosa and a mutant lacking the pyoverdine 17 receptors FpvA and FpvB. -
Supporting Information Appendix: Media Compositions
Supporting Information Appendix: Media compositions Seed media (2% glucose, 0.5% yeast extract, 0.5% meat extract, 0.5% peptone, 0.3% hydrolyzed casein, 0.15% NaCl). AF/MS media (2% glucose or 3% dextrin, 0.2% yeast extract, 0.8% organic soybean flour, 0.1% NaCL, 0.4% CaCO3) (1). Minimal MG Base (for 1L: 50 g maltose monohydrate, 0.2 g MgSO4 heptahydrate, 9 mg FeSO4 heptahydrate, 1 g CaCl2 monohydrate, 1 g NaCL, 21 g 3(N-morphilino)propanesulphonic acid, 11.23 g monosodium glutamate monohydrate, 15 mL 1M potassium phosphate buffer pH = 6.5, 4.5 mL of trace mineral solution consisting of 39 mg CuSO4, 5.7 mg H3BO3, 3.7 mg (NH4)6Mo7O24 tetrahydrate, 6.1 mg MnSO4 monohydrate, 880 mg ZnSO4 heptahydrate in 1 L water) (2). Minimal Media C (for 1L: 5 g L-glutamate, 1 g arginine, 1 g aspartate, 0.5 g K2HPO4 heptahydrate, 1 g MgSO4 heptahydrate, 2 g Na2SO4, 0.01 g ZnSO4 heptahydrate, 0.02 g FeSO4 heptahydrate, 3 g CaCO3, 40 g glucose) (3). J Media (10% sucrose, 3% tryptone soya, 1% yeast extract, 1% MgCl2 hexahydrate) (2). SFM (soya flour mannitol) agar plates (2 % organic soya flour, 2 % mannitol, 2% agar, tap water) (2). General Methods, Materials, and Instrumentation: All DNA manipulations (sub-cloning) were carried out in DH5α E. coli (Zymo Research). Streptomyces ATCC 55365 was obtained from American Type Culture Collection (Manassas, VA) and E. coli BW25113, E. coli BT340, plasmid pKD46, and plasmid pKD3 were obtained from the E. coli Genetic Stock Center (CGCS, Yale University). -
EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use
Ref. Ares(2019)6843167 - 05/11/2019 31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance . -
TETRACYCLINES and CHLORAMPHENICOL Protein Synthesis
ANTIMICROBIALS INHIBITING PROTEIN SYNTHESIS AMINOGLYCOSIDES MACROLIDES TETRACYCLINES AND CHLORAMPHENICOL Protein synthesis Aminoglycosides 1. Aminoglycosides are group of natural and semi -synthetic antibiotics. They have polybasic amino groups linked glycosidically to two or more aminosugar like: sterptidine, 2-deoxy streptamine, glucosamine 2. Aminoglycosides which are derived from: Streptomyces genus are named with the suffix –mycin. While those which are derived from Micromonospora are named with the suffix –micin. Classification of Aminoglycosides 1. Systemic aminogycosides Streptomycin (Streptomyces griseus) Gentamicin (Micromonospora purpurea) Kanamycin (S. kanamyceticus) Tobramycin (S. tenebrarius) Amikacin (Semisynthetic derivative of Kanamycin) Sisomicin (Micromonospora inyoensis) Netilmicin (Semisynthetic derivative of Sisomicin) 2. Topical aminoglycosides Neomycin (S. fradiae) Framycetin (S. lavendulae) Pharmacology of Streptomycin NH H2N NH HO OH Streptidine OH NH H2N O O NH CHO L-Streptose CH3 OH O HO O HO NHCH3 N-Methyl-L- Glucosamine OH Streptomycin Biological Source It is a oldest aminoglycoside antibiotic obtained from Streptomyces griseus. Antibacterial spectrum 1. It is mostly active against gram negative bacteria like H. ducreyi, Brucella, Yersinia pestis, Francisella tularensis, Nocardia,etc. 2. It is also used against M.tuberculosis 3. Few strains of E.coli, V. cholerae, H. influenzae , Enterococci etc. are sensitive at higher concentration. Mechanism of action Aminoglycosides bind to the 16S rRNA of the 30S subunit and inhibit protein synthesis. 1. Transport of aminoglycoside through cell wall and cytoplasmic membrane. a) Diffuse across cell wall of gram negative bacteria by porin channels. b) Transport across cell membrane by carrier mediated process liked with electron transport chain 2. Binding to ribosome resulting in inhibition of protein synthesis A.